CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

(2018) Pamela L. Kunz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.

(2017) Robert Lance Fine et al.   JOURNAL OF CLINICAL ONCOLOGY

A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas

(2016) Laura H. Tang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

(2016) R. Garcia-Carbonero et al.   NEUROENDOCRINOLOGY

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma

(2015) J. Hadoux et al.   ENDOCRINE-RELATED CANCER

Cytotoxic chemotherapy for pancreatic neuroendocrine tumors

(2015) Takuji Okusaka et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas

(2014) Olca Basturk et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

(2013) Robert L. Fine et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

(2013) Fritz-Line Vélayoudom-Céphise et al.   ENDOCRINE-RELATED CANCER

Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy

(2013) Mustafa Khasraw et al.   Expert Review of Anticancer Therapy

Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors

(2013) Pamela L. Kunz et al.   PANCREAS

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

(2012) H. Sorbye et al.   ANNALS OF ONCOLOGY

FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3

(2012) O Hentic et al.   ENDOCRINE-RELATED CANCER

Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors

(2012) Jennifer A. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

(2010) T. Binderup et al.   JOURNAL OF NUCLEAR MEDICINE

Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors

(2009) E. Garin et al.   JOURNAL OF NUCLEAR MEDICINE

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

(2009) Barbro Eriksson et al.   NEUROENDOCRINOLOGY

Clinical and therapeutic aspects of extrapulmonary small cell carcinoma

(2008) Annemiek M.E. Walenkamp et al.   CANCER TREATMENT REVIEWS